Transcriptional characteristics of CD4+ T cells in multiple sclerosis: Relative lack of suppressive populations in bloodShow others and affiliations
2011 (English)In: Multiple Sclerosis Journal, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 17, no 1, p. 57-66Article in journal (Refereed) Published
Abstract [en]
Background: Multiple sclerosis (MS) is hypothetically caused by autoreactive Th1 and Th17 cells, whereas Th2 and regulatory T cells may confer protection. The development of Th subpopulations is dependant on the expression of lineage-specific transcription factors.
Objective: The aim of this study was to assess the balance of CD4(+)T cell populations in relapsing-remitting MS.
Methods: Blood mRNA expression of TBX21, GATA3, RORC, FOXP3 and EBI3 was assessed in 33 patients with relapsing-remitting MS and 20 healthy controls. In addition, flow cytometry was performed to assess T lymphocyte numbers.
Results: In relapsing-remitting MS, diminished expression of FOXP3 (Treg) was found (p < 0.05), despite normal numbers of CD4(+)CD25(hi)Treg. Immunoregulatory EBI3 and Th2-associated GATA3 ([a-z]+) was also decreased in MS (p < 0.005 and p < 0.05, respectively). Expression of TBX21 (Th1) and RORC (Th17) did not differ between patients and controls. Similar changes were observed when analysing beta-interferon treated (n = 12) or untreated (n = 21) patients. Analysis of transcription factor ratios, comparing TBX21/GATA3 and RORC/FOXP3, revealed an increase in the RORC/FOXP3 ratio in patients with relapsing-remitting MS (p < 0.005).
Conclusion: Our findings indicate systemic defects at the mRNA level, involving downregulation of beneficial CD4(+)phenotypes. This might play a role in disease development by permitting activation of harmful T cell populations.
Place, publisher, year, edition, pages
Sage Publications, 2011. Vol. 17, no 1, p. 57-66
Keywords [en]
EBI3, FOXP3, multiple sclerosis, RORC, T cells, transcription factors
National Category
Clinical Medicine
Research subject
Immunology
Identifiers
URN: urn:nbn:se:oru:diva-97547DOI: 10.1177/1352458510381256ISI: 000285867200006PubMedID: 20847001Scopus ID: 2-s2.0-78650990962OAI: oai:DiVA.org:oru-97547DiVA, id: diva2:1638194
Funder
Swedish Society of MedicineSwedish Association of Persons with Neurological Disabilities
Note
Funding agencies:
Hospital of Linköping
Linköping Society of Medicine
County Council of Östergötland
2022-02-162022-02-162025-02-18Bibliographically approved